SCHEMBL18208259

SCHEMBL18208259

O=C(N[C@H]1CC[C@H](C(=O)Nc2ccc(F)cc2Cl)CC1)c1[nH]cnc1C(=O)N1CCC1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HPGD P15428 1/20 0.43
▸ MAPT P10636 3/20 0.42
▸ CHRM4 P08173 1/20 0.41
▸ USP2 O75604 1/20 0.40
▸ POLB P06746 2/20 0.39
▸ KMT2A Q03164 2/20 0.39
▸ EPHX2 P34913 2/20 0.39
▸ ALPL P05186 1/20 0.38
▸ ALPI P09923 1/20 0.38
▸ ALPG P10696 1/20 0.38
▸ MEN1 O00255 1/20 0.38
▸ SMN1; SMN2 Q16637 1/20 0.38
▸ LMNA P02545 1/20 0.38
▸ TP53 P04637 1/20 0.38
▸ THRB P10828 1/20 0.38
▸ GRM4 Q14833 1/20 0.37
▸ PDE10A Q9Y233 1/20 0.37
▸ ALOX15 P16050 1/20 0.37
▸ GSK3B P49841 1/20 0.37
▸ MAPK14 Q16539 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18208265 1.00 HPGD (0.43) HPGDMAPTCHRM4USP2POLB
SCHEMBL20205221 0.93 POLB (0.44) HPGDMAPTCHRM4POLBKMT2A
SCHEMBL20205237 0.91 MAPT (0.38) HPGDMAPTCHRM4USP2POLB
SCHEMBL18208353 0.90 HPGD (0.41) HPGDMAPTCHRM4POLBKMT2A
SCHEMBL18208350 0.90 HPGD (0.41) HPGDMAPTCHRM4POLBKMT2A
SCHEMBL20201142 0.89 HPGD (0.49) HPGDMAPTCHRM4POLBKMT2A
SCHEMBL18208331 0.89 HPGD (0.40) HPGDMAPTCHRM4POLBKMT2A
SCHEMBL18208330 0.89 HPGD (0.40) HPGDMAPTCHRM4POLBKMT2A
SCHEMBL18208293 0.88 CCNA2 (0.41) HPGDMAPTCHRM4POLBALPL
SCHEMBL18208291 0.88 CCNA2 (0.41) HPGDMAPTCHRM4POLBALPL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180148418-A1 AMIDO-SUBSTITUTED CYCLOHEXANE DERIVATIVES BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2018-05-31 — — US claimed
US-20180148418-A1 AMIDO-SUBSTITUTED CYCLOHEXANE DERIVATIVES BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2018-05-31 — — US disclosed
US-20180148418-A1 AMIDO-SUBSTITUTED CYCLOHEXANE DERIVATIVES BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2018-05-31 — — US disclosed
US-20180148418-A1 AMIDO-SUBSTITUTED CYCLOHEXANE DERIVATIVES BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2018-05-31 — — US disclosed
EP-3292107-A1 AMIDO-SUBSTITUTED CYCLOHEXANE DERIVATIVES Bayer Pharma Aktiengesellschaft (DE) 2018-03-14 — — EP disclosed
WO-2016177658-A1 AMIDO-SUBSTITUTED CYCLOHEXANE DERIVATIVES BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2016-11-10 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180148418-A1 AMIDO-SUBSTITUTED CYCLOHEXANE DERIVATIVES C1R, C9, C1S HPGD 565/4885MAPT 4434/4885CHRM4 2150/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback